Joelle retweeted
Can systemic treatment intensification reduce recurrence risk in high-risk localised prostate cancer? #ESMO26 presentation of interim results from the #DASLHiCaP #CCTG PR.22 international (ANZUP 1801) clinical trial. buff.ly/IokpCQt
Joelle retweeted
VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert
Joelle retweeted
Rather a brilliant discussion at the presidential #ESMO26 for the DASL very high risk prostate cancer trial
The future is patient selection. The clearest indication is in pateints with N1 disease supported by results from thr other trials @OncoAlert @ChrisSweens1 @Uromigos
Joelle retweeted
With time I think we’ll see an OS!
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
Joelle retweeted
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
#ESMO26 Proteus Debate:
1) Are we just seeing the impact of treatment intensification in occult mCSPC?
2) Are we putting mCSPC patients through unnecessary, highly invasive surgery. With severe systemic toxicities and surgical morbidity, how do we justify and weigh the QoL?
Joelle retweeted
Elegant talk by @MattGalsky looking at molecular drivers and subtypes in relation to treatment benefit in #NIAGARA
#ESMO26 #Day2 @myESMO @OncoAlert
Joelle retweeted
What a start for #ESMO26 #Day2
What comes after EV-Pembro ?
Excellent overview of sequential systemic therapies in advanced #UC by #DrYohannLoriot
@myESMO @OncoAlert
Joelle retweeted
Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC.
2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone.
EFS HR 0.40 vs 0.71 (each vs control).
pCR 58.8% vs 25.3% vs 10.3%.
#ESMO26 #BladderCancer @myESMO @OncoAlert
Joelle retweeted
⚠️ Visitors, workers and students in Canada: It is illegal to work in Canada without authorization. In most cases, you need a valid work permit.
Learn why it’s important to follow the rules for working in Canada: bit.ly/4qFvI6o
Joelle retweeted
Resident Journal Club | Sept 8 • 12 PM ET OPERA → APHRODITE: Resident‑led look at emerging rectal #brachytherapy evidence & real‑world implementation barriers. Tailored for #residents but open to all physicians & healthcare providers. bit.ly/4niSlLO #radonc
Joelle retweeted
Today is world #kidneycancer day! We have made lots of progress but so much work to do! 😃 ikcc.org/world-kidney-cancer… #kcsm @IKCCorg
✨ What keeps the field's top leaders moving forward?
Watch the final part of our interview with Prof Laura Dawson & Prof David Palma as they share what continues to inspire them every day in #radonc.
🎥 Full video below! 👇
#ESTRO26 #Radiotherapy #Inspiration #CancerResearch
Joelle retweeted
If you have 5 minutes give this a listen :)
A Great Day 4 of #ESTRO26 interview with the 2026 ESTRO Honorary Member Awardees Dr. Laura Dawson & Dr. David Palma 🇨🇦 What advice would you give to early career professionals entering the field
#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72
Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth
Joelle retweeted
ABS is kicking off 2026 with a deep dive into challenging HDR + LDR #prostate #brachytherapy cases. Our expert panel will walk through patient selection, imaging considerations, and strategies for managing toxicities. bit.ly/4niSlLO #Thisisbrachytherapy #RadOnc #MedEd
Joelle retweeted
#HRQOL #oligoprog #SBRT
🔥RADIANT - phII oligoprog GI, GU, breast
🔵 secondary outcome - HRQOL
⬇️ mean global health SS but not clinically significant at 6m
🔵disease progression predictor of worse HRQOL on MVA
🔵if no prog HRQOL was stable or improved in 83%
1/
Joelle retweeted
🎉 Congratulations to the 2025–2026 ABS Board of Directors and Officers! Your leadership will shape the future of brachytherapy, and we’re excited for what’s ahead. 💙 @KamravaMD @PeteRossiMD @marisakollmeier #Brachytherapy #ThisisBrachytherapy #BrachytherapyLeadership


































